Switching to Biosimilar Infliximab Is Safe and Effective

Biosimilars are effective in inducing remission in inflammatory bowel disease, but the current randomized trial is the first to compare switching patients who were stable on infliximab to a biosimilar (FDA-approved CT-P13).

The double-blind, phase IV study included 482 patients, of whom 32% had Crohn disease, 19% ulcerative colitis, 19% spondyloarthritis, 16% rheumatoid arthritis, 7% chronic plaque psoriasis, and 6% psoriatic arthritis.

During the one-year study, disease worsening occurred in 26% on infliximab and 30% on biosimilar (no difference). Rates of adverse events were similar between groups.